ABCL
AbCellera Biologics Inc.NASDAQHealthcare$3.52+0.28%ClosedMarket Cap: $1.07B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.92
P/S
14.20
EV/EBITDA
-6.02
DCF Value
$-2.80
FCF Yield
-16.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-289.0%
Net Margin
-194.9%
ROE
-14.2%
ROA
-11.5%
ROIC
-13.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $44.9M | 100.0% | $-28.6M | $-8.9M | $-0.03 | — |
| FY 2025 | $75.1M | 100.0% | $-217.1M | $-146.4M | $-0.49 | — |
| Q3 2025 | $9.0M | 100.0% | $-76.3M | $-57.1M | $-0.19 | — |
| Q2 2025 | $17.1M | 100.0% | $-49.6M | $-34.7M | $-0.12 | — |
| Q1 2025 | $4.2M | 100.0% | $-62.7M | $-45.6M | $-0.15 | — |
| Q4 2024 | $5.0M | 100.0% | $-72.8M | $-34.2M | $-0.12 | — |
| FY 2024 | $28.8M | 100.0% | $-314.8M | $-162.9M | $-0.55 | — |
| Q3 2024 | $6.5M | 100.0% | $-93.7M | $-51.1M | $-0.17 | — |
| Q2 2024 | $7.3M | 100.0% | $-93.5M | $-36.9M | $-0.13 | — |
| Q1 2024 | $10.0M | 100.0% | $-54.9M | $-40.6M | $-0.14 | — |
| Q4 2023 | $9.2M | 100.0% | $-66.1M | $-47.1M | $-0.16 | — |
| FY 2023 | $38.0M | 100.0% | $-237.2M | $-146.4M | $-0.51 | — |